<scp>PD</scp>‐L1 expression and survival among melanoma patients treated with standard immunotherapy or chemotherapy
Torben Steiniche(Aarhus University), Wei Zhou(Broad Institute), Inge Marie Svane(Copenhagen University Hospital), Yu Feng(Xiangyang Central Hospital), Lars Bastholt(Odense University Hospital), Allan Vestergaard Danielsen(Aarhus University Hospital), Henrik Schmidt(Aarhus University Hospital), Z. Wang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Patricia Switten Nielsen(Aarhus University Hospital), Marisa Dolled‐Filhart(Fox Chase Cancer Center), Michael Busch-Sørensen(Center for Clinical & Basic Research), Kenneth Emancipator(Merck & Co., Inc., Rahway, NJ, USA (United States)), Russell Weiner(Mochida Pharmaceutical (Japan))
Cited by 4
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
|New England Journal of Medicine|2016|1.3k